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Background: We previously demonstrated that lovastatin decreases cyst volume and improves kidney function in
the Han:SPRD (Cy/+) rat model of ADPKD. Since endothelial dysfunction and inflammatory activity are evident in
patients with ADPKD, we investigated whether lovastatin reduces the inflammation and vascular dysfunction and
improves kidney cell energy metabolism of Cy/+ rats.
Methods: Cy/+ and normal littermate control animals (+/+) were treated with either lovastatin (4 mg/kg/day) or
vehicle (ethanol) from 3–8 weeks of age. 1H-NMR analysis was performed on water-soluble and lipid kidney fractions
following perchloric acid extraction. Targeted liquid chromatography-tandem mass spectrometry (LC-MS/MS) was used
to assess endothelial dysfunction, oxidative stress and inflammation markers in plasma and kidney tissue extracts.
Results: Cy/+ rats showed perturbations in fatty acid metabolism and increased synthesis of pro-inflammatory
lipoxygenases-produced bioactive lipids was observed. Lovastatin decreased inflammatory markers, specifically
13-HODE, 12-HETE and leukotriene B4. In Cy/+ rats, lovastatin reduced the elevated homocysteine and allantoin plasma
levels and increased arginine, that is known to positively affect NO production.
In terms of kidney cell metabolism, Cy/+ rats showed reduced Krebs cycle activity. Treatment with lovastatin increased
the Krebs cycle activity as well as the glycolytical lactate production, thus improving the overall energy state of the
cystic kidney.
Conclusion: As previously described, lovastatin was able to decrease kidney weight and cyst volume density in
Cy/+ rats. The decrease in cyst volume was accompanied by a reduction in arachidonic acid-mediated
inflammation markers, the normalization of metabolism of NO precursors and the improvement of kidney energy
cell metabolism.
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Autosomal dominant polycystic kidney disease (ADPKD)
is the most common life-threatening hereditary renal dis-
ease, affecting approximately 1 in 200–400 individuals [1].
ADPKD is responsible for approximately 4% of end-stage
renal disease (ESRD) in the United States and 8-10% in
Europe [1]. The condition is characterized by progressive* Correspondence: Jelena.Klawitter@ucdenver.edu
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reproduction in any medium, provided the ordevelopment of kidney cysts with renal enlargement
and associated loss of renal function, such that approxi-
mately half of patients with ADPKD develop ESRD by
60 years of age [2].
Recent clinical studies have demonstrated the efficacy
of statins in ameliorating progressive nephropathy [3-5].
Statins are known to improve renal blood flow [3,6] and
glomerular filtration rate (GFR) by increasing single
nephron GFR [7]. Statin treatment is also associated
with enhanced vascular and glomerular nitric oxide pro-
duction and attenuation of vascular inflammation [8].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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shown to be beneficial in experimental angiotensin (Ang)
II-mediated renal injury. Specifically, rats transgenic for
human renin and angiotensinogen develop early hyperten-
sion, cardiac hypertrophy, and renal damage, with marked
albuminuria and focal cortical necrosis [9]. Treatment of
these rats with cerivastatin was associated with significant
reductions in systolic blood pressure, serum creatinine,
and albuminuria. Cerivastatin treatment was also associ-
ated with diminished inflammation as assessed by intercel-
lular adhesion molecule-1 and vascular cell adhesion
molecule-1 expression and renal infiltration with neutro-
phils or monocytes.
Beneficial effects of statin therapy on renal disease
have also been observed in humans. Post-hoc subgroup
analysis of the CARE study, a randomized trial of prava-
statin vs. placebo, demonstrated that statin treatment
significantly reduced the rate of decline of renal function
in patients with moderate to severe chronic renal insuffi-
ciency, particularly in those with proteinuria [10,11]. In
an open label study, atorvastatin administered with
angiotensin-converting-enzyme inhibitor (ACEI) was
also associated with decreased progression of renal dis-
ease [5]. These beneficial effects have been attributed to
modulation of glomerular mesangial and interstitial in-
flammation and are independent of reduction in lipid
concentrations.
The effect of statin treatment on renal function and
structure has previously been studied in ADPKD. Specific-
ally, van Dijk et al. have demonstrated increases in renal
blood flow and GFR in response to a 4-week period
of simvastatin treatment in 10 normocholesterolemic,
normotensive patients with ADPKD [6]. It has also been
proposed that statins may mediate progression of struc-
tural disease in ADPKD. In this regard, lovastatin has been
shown in male Cy/+ rats to reduce the severity of PKD as
assessed by kidney size, volume density of cysts, and blood
urea nitrogen (BUN) concentration [12].
Although the underlying mechanisms are not well
understood, it is believed that the renoprotective effects
of statins are mediated by inhibition of G-proteins with
resultant decreased cell proliferation. In addition, we
have reported that statin therapy offers structural and
functional benefits, including increased renal blood flow
(RBF) and decreased BUN, independent of a change in
mean arterial pressure (MAP), while ACE inhibitor ther-
apy demonstrated structural benefit in association with a
decrease in MAP [13].
Based on this knowledge, we hypothesized that, in
addition to reducing the renal cyst volume, statins also
a) reduce the inflammation and resulting vascular dys-
function and b) improve kidney cell energy metabolism
in Cy/+ rats with PKD. To test our hypothesis we ana-
lyzed a comprehensive panel of endothelial dysfunctionand inflammation markers in plasma and kidney tissue
samples of Cy/+ rats treated with lovastatin for five weeks
compared to normal control rats. In addition, a 1H-NMR-
based metabolomics strategy was used to study changes in
kidney cell energy metabolism as a result of PKD develop-
ment and following lovastatin therapy of PKD rats.
Methods
Animals
The study was conducted in male heterozygous (Cy/+)
and normal littermate control (+/+) Han:SPRD rats. The
male Cy/+ rat develops clinically detectable polycystic
kidney disease by 8 weeks of age, as evidenced by a
doubling of kidney size and kidney failure compared
with +/+ control rats [14,15]. A colony of Han:SPRD rats
was established in our animal care facility from a litter
that was obtained from the Polycystic Kidney Program
at the University of Kansas Medical Center.
All animal protocols were approved by the University of
Colorado Institutional Animal Care and Use Committee,
and animal care was in accordance with the National
Institutes of Health guidelines for ethical animal research
(NIH publication No. 80–123). All animals were housed
in cages in a temperature and light-controlled environ-
ment with free access to tap water and standard chow
ad libitum.
Experimental protocol
Male Cy/+ and +/+ rats were weaned at 3 weeks of age.
The Cy/+ rats were treated with either lovastatin (4 mg/
kg/day sc) or vehicle (100% ethanol sc, volume equal to
lovastatin-treated group) for 5 weeks from 3 to 8 weeks
of age. Water intake was monitored. The mean water
intake for each rat for the 5-wk duration of the study
was 817 ± 19 ml.
Lovastatin was obtained from Merck Sharp & Dohme
Research Laboratories (Rahway, NJ). The dose of lova-
statin was based on rat studies in ADPKD [12] and ex-
perimental nephrotic syndrome [16]. At the end of the
study period, rats were anesthetized by an intraperito-
neal injection of pentobarbital sodium (50 mg/kg body
wt) and subjected to blood pressure and renal blood flow
(RBF) studies before the kidneys were removed and
weighed. The left kidney was fixed in 4% paraformalde-
hyde in PBS for 120 min and then put into 70% ethanol
and embedded in paraffin for histological examinations.
The right kidney was frozen at −70°C and used for meta-
bolic analyses. EDTA plasma was collected as well and
kept frozen at −70°C prior to analysis.
Analysis of bioactive lipid mediators
Bioactive lipid mediators were analyzed using a high-
performance liquid chromatography (HPLC)-tandem
mass spectrometry (MS/MS) assay that was a modification
Figure 1 Fatty acid metabolism. Linoleic acid is metabolized by 5-LOX to 9-HODE, and by 15-LOX to 13-HODE. Arachidonic acid can be
metabolized by COX enzymes to prostaglandins; through 5-LOX and 12/15-LOX enzymes into 4-series leukotrienes (LK) and HETE compounds:
5-HETE, 12-HETE, 15-HETE, 11-HETE, 9-HETE and 8-HETE; and by cytochrome P450 enzymes to HETEs including 20-HETE. Eicosapentaenoic acid is
metabolized to HEPE compounds, mainly 5-HEPE, 12-HEPE and 15-HEPE. Docosahexanoic acid can be metabolized by 15-LOX to 17(S)HDHA.
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of EDTA plasma, 800 μL of internal standard containing
methanol/ZnSO4 (70:30, v/v) solution (2 ng/mL mixture
of internal standards, see below) were added. The homog-
enized kidney tissue (approximately 100 mg) was extracted
in 1 mL of methanol/acetonitrile (1:1 v/v) and as previ-
ously described for plasma, 200 μL of extract was com-
bined with 800 μL of internal standard containing
methanol/ZnSO4 (70:30, v/v) solution (2 ng/mL mixture
of internal standards, see below). The samples were
vortexed for 10 minutes, centrifuged for 10 minutes at
13,000 g and transferred into a HPLC vial.
Fifty μL of the supernatant was injected into an online
extraction LC-MS/MS system. The analytical column and
solvents as described by Masoodi et. al. [17] were used.
An API5000 mass spectrometer (AB Sciex, Concord, ON)
was run in the positive electrospray ionization mode (ESI).
The following hydroxyl fatty acids were quantified using
the previously described MRM transitions [17]: hydroxy-
octadecadienoic acids (9-HODE and 13-HODE), hydroxy-
eicosapentaenoic acids (5-HEPE, 8-HEPE, 9-HEPE,
12-HEPE, 15-HEPE), hydroxy-eicosatetraenoic acids (5-
HETE, 8-HEYE, 9-HETE, 12-HETE, 15-HETE, 20-HETE),
17-hydroxy-docosahexaenoic acid (17S-HDHA), resolving
D1 (RvD1) and leukotriene B4 (LtB4). All compounds
including the internal standards were purchased from
Cayman Chemicals (Ann Arbor, MI).
Endothelial dysfunction markers including adenosine,
arginine (Arg), asymmetric and symmetric dime-
thylarginine (ADMA and SDMA), cysteine (Cys),glutathione, homocysteine (Hcy), methionine (Met), S-
adenosylhomocysteine (SAH) and S-adenosylmethionine
(SAM) were quantified in EDTA plasma using a vali-
dated high-performance liquid chromatography-mass
spectrometry (HPLC-MS/MS) assay. For more details,
please refer to the Additional file 1.
The API5000 mass spectrometer (AB Sciex, Concord,
ON) was run in the positive ESI mode using MRM. The
following mass transitions were used (mass/charge, m/z):
adenosine: 268.1→ 136.1; Arg: 175.2→ 70.1; ADMA:
203.2→ 46.2; SDMA: 203.2→ 172.2; d7-ADMA (internal
standard): 210.2→ 77.2; cystine: 122.0→ 75.9; d2-cysteine
(internal standard): 124.0→ 77.9; Hcy: 136.1→ 90.1; d4-
Hcy (internal standard): 140.1→ 94.1; Met: 150.1→ 104.0;
d3-Met (internal standard): 153.1→ 107.0; glutathione:
308.0→ 179.0; S-methylglutathione: 322.0→ 176.0; SAM:
399.0→ 250.1; d3-SAM (internal standard): 402.0→
136.2; SAH: 385.0→ 136.2 and d5-SAH (internal stand-
ard): 391.0→ 137.2.
1H-NMR spectroscopy
1H-NMR analysis of kidney tissue samples was performed
using a Varian INOVA NMR 500 MHz spectrometer
equipped with 5-mm HCN-PFG probe (Varian, Palo
Alto, CA). Following perchloric acid (PCA) extraction
allowing for water-soluble and lipid fraction separ-
ation [18], lyophilized extracts were re-dissolved in
0.5 mL D2O and 1 mL of deuterated methanol/
chloroform mixture (2:1, v:v) for water-soluble or
lipid fraction extracts, respectively. The pH was
Figure 2 Changes in pro-inflammatory lipoxygenases-mediated linoleic acid metabolites 9-HODE and 13-HODE in (A) plasma and (B)
kidney tissue of healthy (+/+) and Cy/+ rats. Cy/+ rats were additionally treated with 4 mg/kg/day lovastatin for 5 weeks. 9-HODE is mainly
produced by 5-LOX, 13-HODE by 15-LOX. *p < 0.05 vs Cy/+ plus lovastatin, **p < 0.01 vs. +/+,***p < 0.001 vs. +/+; n = 5-15.
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trimethylsilyl propionic-2,2,3,3,-d4 acid dissolved in
D2O to 50 mmol/L) was used for metabolite chemical
shift assignment (0 ppm) and quantification [18]. To
suppress water in the extracts, a standard Varian pre-
saturation sequence was used. 1H-NMR spectra were
recorded at 500 MHz using spectral width of 12 ppm
and 32 K data arrays, and 64 scans with 90° flip
angle. The D1 time was 14.8 sec, which was required
to fully relax all protons in the samples including the
TMSP protons. Data analysis of the NMR data was
performed using the TopSpin software (Bruker,
Rheinstetten, Germany). Drift correction, zero filling
from 32 K to 64 K data points and a Gaussian win-
dow function were applied to the free induction
decay (FID) prior to Fourier transformation. Prior to
integration, all 1H-NMR spectra were manually
corrected for phase and baseline distortions. All NMR
experiments were performed at the Systems Biology
University of Colorado Cancer Center Core.Statistical analysis
All numerical data is presented as means ± standard devi-
ation. Analysis of variance (ANOVA) followed by the
Tukey post-hoc test was used to test for group differences.
The significance level was p < 0.05 for all tests. SPSS statis-
tics was used (version 19, IBM/SPSS, Chicago, IL).
Results
Fatty acid metabolism
Pathways of fatty acid metabolism considered in the
present study are shown in Figure 1.
Linoleic acid (LA) metabolism
In comparison to their healthy +/+ counterparts,
plasma concentration of 13-HODE, a metabolite pro-
duced from LA by 15-lipoxygenase (LOX), was increased
in cystic Cy/+ animals (Figure 2A). Plasma concentrations
of 9-HODE, a metabolite produced from LA by 5-LOX,
however, did not change (Figure 2A). As a result of lova-
statin therapy, plasma concentrations of 13-HODE were
Figure 3 Changes in pro-inflammatory arachidonic acid metabolites 8-HETE, 9-HETE and 12-HETE in (A) plasma and (B) kidney tissue of
healthy (+/+) and cystic Cy/+ rats. Cy/+ rats were additionally treated with 4 mg/kg/day lovastatin for 5 weeks. 8-HETE and 9-HETE are mainly
produced by 8- and 9-LOX, 12-HETE by 12-LOX. Significance levels are given for Cy/+ control versus +/+ control and Cy/+ plus lovastatin versus
Cy/+ control: *p < 0.05 vs. +/+, **p < 0.01 vs. Cy/+ lovastatin; n = 5-15.
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treated Cy/+ controls (Figure 2A).
In the kidney, the concentrations of 9-HODE as well
as 13-HODE were significantly higher in Cy/+ animals
(Figure 2B). Lovastatin treatment decreased both LA
metabolites to the levels observed in non-cystic +/+ ani-
mals. However, this difference was not statistically sig-
nificant (Figure 2B).
Arachidonic acid (AA) metabolism
Plasma and kidney tissue concentrations of 12-HETE, an
AA metabolite produced by 12-LOX, was significantly
higher in Cy/+ than in +/+ control animals (Figure 3A).
While lovastatin treatment was successful in reducing
circulating 12-HETE plasma levels, the decrease in the
kidney tissue concentrations did not reach statistical sig-
nificance (Figure 3B).
Furthermore, lovastatin was also successful in redu-
cing the plasma concentration of leukotriene B4, a pro-
inflammatory product of AA metabolism generated via5-LOX (Figure 4A). However, no change in the plasma
or kidney tissue concentrations of its precursor 5-HETE
was observed when comparing cystic versus healthy ani-
mals or in Cy/+ animals that received lovastatin therapy
(Figure 4A).
In addition, there was a significant difference in the
kidney tissue concentrations of 15-HETE between the
Cy/+ and control animals (367.8 ± 101.9 ng/mg tissue
in Cy/+ animals versus 177.7 ± 36.2 ng/mg tissue in
control +/+ animals, p < 0.05, n = 4). This difference
was not reflected by 15-HETE plasma concentrations.
Lovastatin reduced the kidney tissue concentrations of
15-HETE to 252.4 ± 83.5 ng/mg tissue (not significant
vs. vehicle-treatment, n = 5).
In addition to the metabolism via LOX enzymes, AA
can be metabolized by cytochrome P450 enzymes and
by cyclooxygenases (COX) (Figure 1). However, no sig-
nificant changes in the kidney concentrations of either
20-HETE (cytochrome P450 metabolite) or prostaglan-
dins (COX metabolite) were noted.
Figure 4 Changes in pro-inflammatory arachidonic acid metabolites (A) 5-HETE, LtB4 and 15-HETE and (B) potentially anti-inflammatory
eicosapentaenoic acid metabolites 12-HEPE, 15-HEPE and (C) 5-HEPE in plasma of healthy (+/+) and cystic Cy/+ rats. Cy/+ rats were
additionally treated with 4 mg/kg/day lovastatin for 5 weeks. Significance levels are given for Cy/+ control versus +/+ control and Cy/+ plus lovastatin
versus Cy/+ control: *p < 0.05 vs. Cy/+ plus lovastatin, **p < 0.01 vs. +/+; n = 5-15.
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In regards to EPA metabolism, no changes in the con-
centrations of 12/15-LOX metabolites 12/15-HEPE
were observed (Figure 4B). However, Cy/+ rats did
show lower plasma levels of anti-inflammatory 5-
HEPE as compared to the healthy controls (Figure 4B).
Lovastatin increased 5-HEPE plasma concentrations
(Figure 4B).Endothelial dysfunction markers
No changes in the plasma concentrations of the endo-
thelial dysfunction markers ADMA and SDMA were
noted in either cystic versus healthy animals or follow-
ing lovastatin treatment (Figure 5A). However, lova-
statin was able to increase the concentration of
arginine, the positive effector of eNOS, in cystic animals
(Figure 5A).
Figure 5 Changes in endothelial dysfunction markers: (A) NO pathway intermediates arginine, ADMA and SDMA and (B) methionine
cycle intermediates HCy, SAM and SAH in healthy (+/+) and cystic (Cy/+) Han:SPRD rats. Cy/+ rats were additionally treated with
4 mg/kg/day lovastatin for 5 weeks. Significance levels are given for Cy/+ control versus +/+ control and Cy/+ plus lovastatin versus Cy/+ control:
*p < 0.05 vs. Cy/+ plus lovastatin, **p < 0.01 vs. Cy/+, ***p < 0.001 vs. Cy/+ plus lovastatin; n = 5-15.
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via methionine into SAM, SAH, and then back to
homocysteine. Interestingly, cystic animals showed
higher levels of plasma SAM and SAH levels than
the +/+ controls, with no change in homocysteine
(Figure 5B).
Lovastatin reduced homocysteine as well as SAM
plasma concentrations, with interestingly no effect on
SAH concentrations (Figure 5B). At the same time in
the urine, homocysteine, but not SAM concentrations
increased from 24.6 ± 19.5 ng/mg creatinine to 48.5 ±
12.0 ng/mg creatinine (p < 0.05), suggesting an in-
creased excretion rate potentially leading to a reduc-
tion of homocysteine plasma levels.
Kidney glucose metabolism: krebs cycle and glycolysis
The glucose metabolism in the kidneys from Cy/+ animals
was significantly altered in comparison to the +/+ con-
trols. The concentrations of Krebs cycle intermediatescitrate and succinate were significantly lower in the kid-
neys of cystic rats (Table 1). This decrease was accompan-
ied by a decrease of kidney glucose concentration
(Table 1). Concentrations of aspartate and acetate were
also reduced in the kidneys of cystic animals (Table 1).
Interestingly, a product of uric acid oxidation and a
marker of kidney injury, allantoin, increased almost 3-fold
in the Cy/+ rat kidneys (Table 1).
Lovastatin treatment reversed the metabolic changes
induced by the PKD in the Cy/+ rats. The citrate
concentrations were higher than in the untreated ani-
mals and lactate concentrations as well (Table 1),
suggesting a recovery of the energy producing Krebs
cycle and glycolysis pathways. The increased glucose
consumption of the lovastatin-treated kidneys further
lowered intra-kidney glucose concentration (Table 1).
Allantoin levels were significantly lower as well, but
still remained almost 2-fold higher than in the +/+
controls (Table 1).
Table 1 Concentration of water-soluble and lipid metabolites as calculated from rat kidney tissue samples using
1H-NMR
Metabolite +/+ Cy/+ Cy/+ plus lovastatin
Acetate [nmol/g] 553.6 ± 288.8 229.7 ± 139.3* 272.2 ± 70.5
Alanine [nmol/g] 1309.8 ± 300.6 1117.2 ± 412.1 938.3 ± 324.4
Allantoin [nmol/g] 623.2 ± 237.7 1572.1 ± 257.1** 1150.1 ± 227.4*
Aspartate [nmol/g] 584.0 ± 98.2 381.1 ± 30.5* 572.7 ± 75.9**
Citrate [nmol/g] 1366.9 ± 296.8 919.3 ± 150.7* 1419.2 ± 92.2**
Glucose [nmol/g] 1145.5 ± 237.9 806.5 ± 113.2* 674.1 ± 104.6*
Glutamate [nmol/g] 4615.0 ± 461.6 3669.4 ± 806.1* 3690.8 ± 933.9
Glutamine [nmol/g] 1437.1 ± 724.0 1385.9 ± 303.4 1087.4 ± 425.7
Glycine [nmol/g] 4763.2 ± 2284.7 3173.1 ± 391.1 4999.2 ± 2408.0
GPC [nmol/g] 696.9.3 ± 48.2 541.8 ± 122.2* 631.3 ± 222.5
3-Hydroxybutyrate [nmol/g] 442.7 ± 118.8 301.2 ± 43.8* 335.4 ± 97.6
Lactate [nmol/g] 4480.7 ± 1303.0 4729.8 ± 696.7 5876.9 ± 393.5*
Myo-inositol [nmol/g] 8170.4 ± 1606.9 8789.3 ± 2184.8 9258.2 ± 2478.2
Succinate [nmol/g] 3353.4 ± 278.2 2219.6 ± 557.0** 2160.9 ± 420.3
Taurine [μmol/g] 12.0 ± 3.7 11.5 ± 1.6 11.7 ± 2.4
TAG/DAG [μmol/g] 8.5 ± 2.2 5.1 ± 0.8* 5.9 ± 2.2
Δ-2 PUFA [μmol/g] 12.1 ± 2.2 8.0 ± 0.7* 10.0 ± 2.4
Cholines [μmol/g] 1.8 ± 0.5 1.3 ± 0.1 1.6 ± 0.2*
Values are presented as means ± standard deviations (n = 4-5). Significance levels are given for Cy/+ versus +/+ animals and Cy/+ plus lovastatin versus Cy/+
animals: *p < 0.05, **p < 0.01; as determined by ANOVA (with post-hoc pairwise multiple comparison Tukey-test). Abbreviations: DAG: diacylglycerol, GPC:
glycerophosphocholine, PUFA: polyunsaturated fatty acids, TAG: triacylglycerol.
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Patients with ADPKD have an activated pro-inflammatory
phenotype [19,20]. The progression of renal disease and
hypertension in ADPKD in both children and adults is as-
sociated with increases in blood pressure, kidney volume,
and cyst volume density [21-24]. Normotensive ADPKD
patients with preserved renal function show significantly
increased serum levels of vascular inflammatory markers:
intercellular adhesion molecule (ICAM)-1, vascular cell
adhesion molecule-1 (VCAM-1), P-selectin, E-selectin and
soluble Fas (sFas) as compared to healthy controls [25,26].
Furthermore, the inflammation, as indicated by increased
serum levels of pro-inflammatory C-reactive protein and
IL-8, exhibits a graded relationship with kidney function
[27]. Unfortunately, the mechanisms underlying the devel-
opment of inflammation in ADPKD patients are not fully
understood.
Here, we identified elevated plasma concentrations of
pro-inflammatory 12/15-LOX metabolites 13-HODE and
12-HETE in cystic Cy/+ versus +/+ rats. Tissue concentra-
tions of the pro-inflammatory linoleic acid LOX metabo-
lites 9-HODE and 13-HODE, the arachidonic acid LOX
metabolites 12-HETE as well as 8-HETE and 9-HETE
were higher in the kidneys of Cy/+ rats as well. The above
described LOX metabolites have also been shown to dir-
ectly function as key mediators of angiotensin II-inducedrenin inhibition [28,29] and to contribute to high blood
pressure in renovascular hypertension [30].
We have previously shown that treatment with lovastatin
decreases kidney weight and cyst volume density in Han:
SPRD rats [13]. In the present mechanistic biomarker
study, lovastatin was successful in reducing the elevated 13-
HODE and 12-HETE plasma levels in Cy/+ animals. In
addition, treatment of Cy/+ rats with lovastatin reduced the
plasma concentrations of leukotriene B4, possibly through
its effect on 5-LOX. 5-LOX-mediated leukotriene B4
generation has been associated with inflammation,
athereosclerosis, and vascular disease [31,32] and several
cancer types [33]. Interestingly, previous studies have sug-
gested that statins can inhibit the formation of components
of the 5-LOX pathway [34-36]. In the kidney, lovasta-
tin was successful in normalizing the levels of pro-
inflammatory LOX metabolites as well. On the basis of
these observations it can be speculated that a reduction of
12/15-LOX activity should be an attractive target to reduce
angiotensin II-mediated oxidative stress, vascular inflamma-
tion, cell proliferation and endothelial dysfunction [37-39].
Abnormal vascular function is a feature of ADPKD
[40,41]. An increase of ADMA plasma levels in ADPKD pa-
tients with normal creatinine clearance has been reported
previously [42-44]. This increase is probably associated with
the observation that ADPKD patients with normal
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acetylcholine-induced endothelium-derived relaxing factor/
NO responses and constitutive NOS activity in subcutane-
ous resistance vessels dissected from biopsy specimens.
In our animal model of PKD, we did not observe any
changes in arginine, ADMA or SDMA plasma concen-
trations between the Cy/+ and +/+ groups. Cystic ani-
mals, however, showed elevated plasma concentrations
of SAH, that has been reported as an independent risk
factor for development and progression of vascular dis-
eases in patients with renal dysfunction [45-47].
Lovastatin elevated plasma arginine, suggesting its bene-
ficial effect on improving the availability of NO [48]. In
addition, lovastatin reduced plasma Hcy levels in Cy/+
rats. Since elevated HCy plasma concentrations are
regarded as an independent risk factor for development
and progression of vascular diseases in patients with renal
dysfunction [45-47], lovastatin’s ability to reduce HCy adds
to its beneficial effects on the endothelial function.
Previous metabolomics studies showed that kidneys
from Cy/+ rats have reduced concentrations of glucose
and Krebs cycle intermediates citrate, succinate, and
2-oxoglutarate, as well as of the osmolytes betaine, tau-
rine, and glycerophosphocholine [49]. Our study con-
firmed these findings of disrupted mitochondrial Krebs
cycle activity, and therefore reduced energy supply of
the cystic kidney. Lovastatin treatment increased the
citrate as well as lactate concentrations in the kidneys
of treated Cy/+ rats.
Interestingly, Cy/+ rats showed almost 3-fold higher
levels of allantoin, which is formed in rats through the oxi-
dation of uric acid. Lovastatin treatment decreased the al-
lantoin levels in the cystic kidney. Since hyperuricemia has
been implicated in the development and progression of
chronic kidney disease, and we recently showed that higher
serum uric acid levels are associated with earlier onset of
hypertension, larger kidney volume and increased hazard
for ESRD in ADPKD patients [50], the ability of lovastatin
to lower allantoin could represent a potential method for
clinical management of hyperuricemia in ADPKD.
Conclusions
In summary, PKD animals show increased levels of in-
flammatory bioactive lipid markers derived from the me-
tabolism of arachidonic acid by 5-LOX and 12/15-LOX
enzymes. In addition, levels of the endothelial dysfunction
marker SAH are increased as well in plasma of PKD ani-
mals, and PKD kidneys show a decreased Krebs cycle ac-
tivity and an increased production of uric acid oxidation
product allantoin. Lovastatin decreased measured in-
flammatory markers, specifically the above mentioned
13-HODE, 12-HETE and leukotriene B4. In addition, lova-
statin was successful in reducing the elevated homocyst-
eine and allantoin levels and it also increased plasmaarginine, thus positively affecting the NO production and
vascular function in cystic animals. In terms of cell metab-
olism, treatment with lovastatin increased citrate as well
as the glycolytical lactate production, thus improving the
overall energy state of the cystic kidney. Taken together,
our results describe the potential mechanisms of how lov-
astatin reduces PKD and support the clinical studies of
statins that are underway in patients with ADPKD. In
addition, the identified pathways could be used as poten-
tial therapeutic targets for slowing down the cyst growth.
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